BWVI Blue Water Ventures International

Blue Water Ventures International Signs Extension on Pulaski Recovery

Blue Water Ventures International Signs Extension on Pulaski Recovery

Jacksonville, FL, March 17, 2021 (GLOBE NEWSWIRE) --  -- Blue Water Ventures International, Inc. (OTCPK:BWVI) and project partner Endurance Exploration Group, Inc (OTC:EXPL) through its wholly own subsidiary Swordfish Partners have confirmed that both parties have agreed to an extension of the Pulaski Joint Venture through year end 2022.  

The extension will allow the joint venture additional time to complete the recovery on the existing work site of the Pulaski and expand its survey to an additional area of interest, believed to be the resting place of the 2nd half of the Pulaski when she exploded during the night in June 1838.  The current area of work includes the boiler and main common areas of the ship.  The 2nd area of interest should include passenger staterooms and baggage compartments.  Past year’s exploration of the Pulaski site has produced over 500 coins, pocket watches, silver ware sets and copious amounts of shipwreck material.  

While working on the Pulaski recovery, plans are also being made to do an updated survey of the wreck site of the SS North Carolina, nicknamed the Copper Pot Wreck. 

About Blue Water Ventures International, Inc.:

The Company is engaged in the business of conducting archaeologically sensitive recoveries of cargo and artifacts from shipwrecks. Its operations to date have focused on shallow water search and recovery projects in less than 150 feet of water. The Company is now expanding its focus to include deep-water salvage of historic and modern-day shipwrecks. For more information go to 

About Endurance Exploration Group, Inc.:

Endurance Exploration Group, Inc. specializes in historic shipwreck research, subsea search, survey and recovery of lost ship containing valuable cargoes.  Over the last 5 years, Endurance has developed a research database of over 1,400 ships that are known to be lost with valuable cargoes in the world oceans.  For more information go to http://

Forward Looking Statements:

This press release contains forward-looking statements within the meaning of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended. Such forward-looking statements are subject to certain risks and uncertainties including, but not limited to: ability to further strengthen our balance sheet, ability to raise funding for continued operations, ability to successfully and profitably locate additional wrecks and cargos, ability to establish ownership, and other factors. Therefore, actual results may differ materially from those indicated or implied by such forward-looking statements. Except as required by law, the Company disclaims any obligation to publicly update such statements.

Keith Webb

904-215-7601



EN
17/03/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Blue Water Ventures International

 PRESS RELEASE

Psycheceutical Hosts MAPS Founder and Psychedelic Industry Leader Rick...

Psycheceutical Hosts MAPS Founder and Psychedelic Industry Leader Rick Doblin at Its Drug Development Lab Doblin commented on the potential of the company’s NeuroDirect™ ketamine topical cream to help those suffering from PTSD Psycheceutical Chief Visionary Officer Zappy Zapolin and CEO Chad Harman with MAPS Founder Rick Doblin MIAMI, March 29, 2023 (GLOBE NEWSWIRE) -- ("Psycheceutical" or the "Company") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge technologies for the next generation of mental health treatments, hosted Rick Doblin, the Founder and Preside...

 PRESS RELEASE

Psycheceutical Bioscience, Inc. Announces Observational Research Resul...

Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical Cream in Treating PTSD A pre-clinical observational study published in Drug Development & Delivery found that more than 80% of patients experienced relief within minutes of applying NeuroDirect™ ketamine topical creamPatients indicated their thought processes were clearer and more focused, and were more keenly aware of surroundings MIAMI, March 21, 2023 (GLOBE NEWSWIRE) -- ("Psycheceutical" or the "Company") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge tec...

 PRESS RELEASE

Psycheceutical to Conduct the First Ever Phase I and II Clinical Trial...

Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD Psycheceutical ​​enters into agreement with iNGENū to conduct ​human ​clinical trials of NeuroDirect™ ketamine topical ​in AustraliaPhase I trial will study 20 people to test the safety, tolerability, and pharmacokinetics of a single dose of NeuroDirect™ ketaminePhase II trial will study 115 participants with PTSD and look at the effectiveness of NeuroDirect™ ketamine on improving their symptoms MIAMI, Feb. 15, 2023 (GLOBE NEWSWIRE) -- (OTCPK: BWVI) ("Psycheceutical"...

 PRESS RELEASE

Psycheceutical Announces Completion of Pre-IND Meeting with FDA for To...

Psycheceutical Announces Completion of Pre-IND Meeting with FDA for Topical Ketamine Drug to Treat PTSD Company intends to pursue 505(b)(2) regulatory pathway for novel topical formulation of ketamine for the treatment of PTSD MIAMI, Feb. 02, 2023 (GLOBE NEWSWIRE) -- (OTCPK: BWVI) ("Psycheceutical" or the "Company"), a bioscience company dedicated to developing cutting-edge brain delivery technologies for the next generation of mental health treatments, is pleased to announce it has completed its pre-Investigational New Drug ("IND") meeting with the U.S. Food and Drug Administration (F...

 PRESS RELEASE

Psycheceutical Bioscience Provisional Patent Application for Novel Ket...

Psycheceutical Bioscience Provisional Patent Application for Novel Ketamine Topical for the Treatment of PTSD Topical ketamine formulations could improve the methods of treating post-traumatic stress disorder (PTSD) MIAMI, Jan. 26, 2023 (GLOBE NEWSWIRE) -- ("Psycheceutical" or the "Company") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge treatments for mental health, has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for the first ketamine topical intended for treating post-traumatic stress disorder (PTSD). The...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch